NexACT enables rectal delivery of biologics, say Apricus Bio

By Alexandria Pešić

- Last updated on GMT

Related tags Rituximab Biogen idec Leukemia

Apricus Biosciences, formerly NexMed, announce preclinical data shows NexACT technology enables rectal delivery of biologics, including human antibodies.

Results from the preclinical pharmacokinetic study delivered rectally with NexACT the antibody Rituxan achieved blood stream concentrations similar to those seen when the drug is delivered via intravenous injection.

“This is the only rectal delivery technology that we are aware of that can deliver systematic, fully humanised antibodies in levels comparable to those obtained via the subcutaneous route,”​ commented Bassam Damaj, CEO of Apricus Biosciences, adding: “The results of this early stage study are highly encouraging.”

The drug Rituxan, is currently delivered subcutaneously or, if a patient is hospitalised, in three cycles of intravenous infusions. Marketed by Genentech and Biogen IDEC, it is prescribed to treat Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukaemia, and Rheumatoid Arthritis.

Damaj believes that reformulating Rituxan for rectal administration could “provide patients the benefit of avoiding painful intravenous infusions and risks of systematic infection.”​ Furthermore, he added, the new formulation has the potential to be administered at home.

Apricus Bio received a $2.7m (€2.0m) cash injection earlier this year to fund the development of NexACT technology, and Damaj maintains “these pre-clinical results further demonstrate the versatility and potential of the NexACT technology as a multi-route delivery vehicle.”

This preceded a distribution deal to market products based on NexACT technology, as well as preclinical research services, throughout Japan in partnership with the Tokyo-based life sciences products company, Cosmo Bio.

In addition, during August, the US drugmaker announced it had strengthened its NexACT intellectual property position with the issuance of a patent by the Israeli Patent Office (IPO) that covers the technology until 2019.

Related news

Show more

Related products

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

State-of-the-Art Virtual Pharma Factory Tour

State-of-the-Art Virtual Pharma Factory Tour

Content provided by METTLER TOLEDO | 04-May-2023 | Event Programme

Join METTLER TOLEDO’s weighing experts on a virtual tour of a state-of-the-art manufacturing facility. On the call, you'll be digitally transported...

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Content provided by Lonza Small Molecules | 28-Mar-2023 | White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Related suppliers

Follow us


View more